A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
Launched by HOFFMANN-LA ROCHE · Feb 26, 2010
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients \>/=18 years of age
- • metastatic colorectal cancer
- • at least 1 measurable lesion according to RECIST v. 1.1
- • patients with disease progression with prior FOLFIRI + Avastin therapy who are not candidates for primary metastasectomy
- • disease progression \</= 8 weeks after last dose of Avastin
- • ECOG \</=2
- • No more than 8 weeks between 1st-line treatment with FOLFIRI + Avastin and 2nd-line treatment with XELOX or FOLFOX + Avastin
- Exclusion Criteria:
- • disease progression \> 8 weeks after last Avastin administration
- • clinically significant cardiovascular disease
- • CNS disease except for treated brain metastasis
- • history of other malignancies within 2 years prior to start of study treatment (with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix)
- • major surgery, open biopsy, or significant traumatic injury within 28 days prior to start of study treatment
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gent, , Belgium
Merksem, , Belgium
Wilrijk, , Belgium
Kortrijk, , Belgium
Mont Godinne, , Belgium
Edegem, , Belgium
Hasselt, , Belgium
Aalst, , Belgium
Turnhout, , Belgium
Brugge, , Belgium
Hasselt, , Belgium
Bruxelles, , Belgium
Charleroi, , Belgium
Brasschaat, , Belgium
Mechelen, , Belgium
Genk, , Belgium
Bonheiden, , Belgium
Namur, , Belgium
Oostende, , Belgium
Sint Niklaas, , Belgium
Tournai, , Belgium
Aye, , Belgium
Dendermonde, , Belgium
Assebroek, , Belgium
Arlon, , Belgium
Verviers, , Belgium
Montigny Le Tilleul, , Belgium
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials